Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
1.620
-0.110 (-6.36%)
At close: Oct 22, 2025, 4:00 PM EDT
1.630
+0.010 (0.62%)
After-hours: Oct 22, 2025, 7:59 PM EDT
Humacyte Revenue
Humacyte had revenue of $301.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $818.00K.
Revenue (ttm)
$818.00K
Revenue Growth
n/a
P/S Ratio
264.19
Revenue / Employee
$3,718
Employees
220
Market Cap
303.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.57M | 302.00K | 23.91% |
| Dec 31, 2021 | 1.26M | -228.00K | -15.29% |
| Dec 31, 2020 | 1.49M | -4.70M | -75.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
HUMA News
- 15 days ago - Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering - GlobeNewsWire
- 16 days ago - Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™ - GlobeNewsWire
- 23 days ago - Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus - GlobeNewsWire
- 4 weeks ago - Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG) - GlobeNewsWire
- 5 weeks ago - Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™ - GlobeNewsWire
- 2 months ago - Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress - Seeking Alpha
- 2 months ago - Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire